Trial reportBMC gastroenterology2018
Additional hepatic
Trial report in BMC gastroenterology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02067988 (Adjuvant Hepatic Holmium-166-radioembolization in Patients With Unresectable Liver Metastases of Neuroendocrine Origin, Who Have Been Treated With Lutetium-177-dotatate), which is not on this map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Adjuvant Hepatic Holmium-166-radioembolization in Patients With Unresectable Liver Metastases of Neuroendocrine Origin, Who Have Been Treated With Lutetium-177-dotatate
Who cites it
17 citing papers in PubMed, 47 citations in OpenAlex.
- Efficacy and evaluation of dose-response relationship of selective internal radiation therapy for the management of liver metastases in neuroendocrine neoplasia.European journal of nuclear medicine and molecular imaging · 2026Trial
- Radionuclide theranostics: advances and clinical applications in lung cancer.Frontiers in oncology · 2026Review
- Radioembolization for neuroendocrine tumors: procedure, application and clinical outcomes.Endocrine oncology (Bristol, England) · 2025Review
- Dose-effect relationships in neuroendocrine tumour liver metastases treated with [European journal of nuclear medicine and molecular imaging · 2024Article
- Automatic healthy liver segmentation for holmium-166 radioembolization dosimetry.EJNMMI research · 2023Article
- Article
- Advances in Radionuclides and Radiolabelled Peptides for Cancer Therapeutics.Pharmaceutics · 2023Review
- Peptide Receptor Radionuclide Therapy.The Journal of clinical endocrinology and metabolism · 2022Article
- The Evolving Role of Radioembolization in the Treatment of Neuroendocrine Liver Metastases.Cancers · 2022Review
- Article
- Review
- Inflammatory markers and long term hematotoxicity of holmium-166-radioembolization in liver-dominant metastatic neuroendocrine tumors after initial peptide receptor radionuclide therapy.EJNMMI research · 2022Article
- Prophylactic Peripheral Blood Stem Cell Collection in Patients with Extensive Bone-Marrow Infiltration of Neuroendocrine Tumours Prior to Peptide Receptor Radionuclide Therapy withPharmaceuticals (Basel, Switzerland) · 2021Article
- Somatostatin receptor radionuclide therapy in neuroendocrine tumors.Endocrine-related cancer · 2021Review
- QuantitativeEJNMMI physics · 2020Article
- SimultaneousEJNMMI physics · 2020Article
- The various therapeutic applications of the medical isotope holmium-166: a narrative review.EJNMMI radiopharmacy and chemistry · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNeuroendocrine tumours (NET) consist of a heterogeneous group of neoplasms with various organs of origin. At diagnosis 21% of the patients with a Grade 1 NET and 30% with a Grade 2 NET have distant metastases. Treatment with peptide receptor radionuclide therapy (PRRT) shows a high objective response rate and long median survival after treatment. However, complete remission is almost never achieved. The liver is the most commonly affected organ in metastatic disease and is the most incriminating factor for patient survival. Additional treatment of liver disease after PRRT may improve outcome in NET patients. Radioembolization is an established therapy for liver metastasis. To investigate this hypothesis, a phase 2 study was initiated to assess effectiveness and toxicity of holmium-166 radioembolization (
methodsThe HEPAR PLUS trial ("Holmium Embolization Particles for Arterial Radiotherapy Plus DISCUSSION: This is the first prospective study to combine PRRT with
trial registrationClinicaltrials.gov NCT02067988 , 13 February 2014. Protocol version: 6, 30 november 2016.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.